Recommendation of the President – Givlaari (givosiran)
On 29 September 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 129/2025 on the appraisal of drug Givlaari (givosiran) under drug program B.128.FM. “Treatment of patients with acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older (ICD-10: E80.2)”